Epirubicin
Smoldering Plasma Cell Myeloma
M.D. Anderson Cancer CenterEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Smoldering Plasma Cell Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Leflunomide City of Hope Medical Center | Phase 2 | B |
Pomalidomide Mayo Clinic | Phase 2 | CCC |
Isatuximab University College, London | Phase 2 | CCC |
Iberdomide Emory University | Phase 2 | CCC |
Cholestyramine City of Hope Medical Center | Phase 2 | CCC |
Anakinra Mayo Clinic | Phase 1 | CC |
Pembrolizumab M.D. Anderson Cancer Center | Early Phase 1 | C |
PROPRANOLOL Roswell Park Cancer Institute | N/A | D |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →